FISEVIER

Contents lists available at ScienceDirect

## Journal of Infection

journal homepage: www.elsevier.com/locate/jinf



## Corrigendum

Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [] Infect 84(6) (2022) 795–813, 5511]



Xinxue Liu <sup>a</sup>, Alasdair PS Munro <sup>b,c</sup>, Shuo Feng <sup>a</sup>, Leila Janani <sup>d</sup>, Parvinder K Aley <sup>a,e</sup>, Gavin Babbage <sup>b</sup>, David Baxter <sup>f</sup>, Marcin Bula <sup>g</sup>, Katrina Cathie <sup>b,c</sup>, Krishna Chatterjee <sup>h</sup>, Wanwisa Dejnirattisai <sup>i</sup>, Kate Dodd <sup>g</sup>, Yvanne Enever <sup>j</sup>, Ehsaan Qureshi <sup>k</sup>, Anna L. Goodman <sup>l,m</sup>, Christopher A Green <sup>k</sup>, Linda Harndahl <sup>n</sup>, John Haughney <sup>o</sup>, Alexander Hicks <sup>n</sup>, Agatha A. van der Klaauw <sup>p</sup>, Jonathan Kwok <sup>q</sup>, Vincenzo Libri <sup>r</sup>, Martin J Llewelyn <sup>s</sup>, Alastair C McGregor <sup>t</sup>, Angela M. Minassian <sup>a,u</sup>, Patrick Moore <sup>v</sup>, Mehmood Mughal <sup>f</sup>, Yama F Mujadidi <sup>e</sup>, Kyra Holliday <sup>w</sup>, Orod Osanlou <sup>x</sup>, Rostam Osanlou <sup>y</sup>, Daniel R Owens <sup>b,c</sup>, Mihaela Pacurar <sup>b,c</sup>, Adrian Palfreeman <sup>z</sup>, Daniel Pan <sup>z</sup>, Tommy Rampling <sup>r</sup>, Karen Regan <sup>aa</sup>, Stephen Saich <sup>b</sup>, Teona Serafimova <sup>l</sup>, Dinesh Saralaya <sup>aa</sup>, Gavin R Screaton <sup>i</sup>, Sunil Sharma <sup>s</sup>, Ray Sheridan <sup>ab</sup>, Ann Sturdy <sup>t</sup>, Piyada Supasa <sup>i</sup>, Emma C Thomson <sup>o,ac</sup>, Shirley Todd <sup>ab</sup>, Chris Twelves <sup>w</sup>, Robert C. Read <sup>b,c</sup>, Sue Charlton <sup>ad</sup>, Bassam Hallis <sup>ad</sup>, Mary Ramsay <sup>ae</sup>, Nick Andrews <sup>ae</sup>, Teresa Lambe <sup>a</sup>, Jonathan S Nguyen-Van-Tam <sup>af</sup>, Victoria Cornelius <sup>d</sup>, Matthew D Snape <sup>a,e</sup>, Saul N Faust <sup>b,c,\*</sup>, the COV-BOOST study group

- <sup>a</sup> Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK
- <sup>b</sup> NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK
- <sup>c</sup> Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK
- <sup>d</sup> Imperial Clinical Trials Unit, Imperial College London, London, UK
- e NIHR Oxford Biomedical Research Centre, Oxford, UK
- <sup>f</sup> Stockport NHS Foundation Trust, Stockport, UK
- g NIHR Liverpool and Broadgreen Clinical Research Facility, Liverpool, UK
- h NIHR Cambridge Clinical Research Facility, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
- <sup>1</sup> Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK
- <sup>j</sup> PHARMExcel, Welwyn Garden City, Hertfordshire, UK
- k NIHR/Wellcome Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
- <sup>1</sup>Department of Infection, Guy's and St Thomas' NHS Foundation Trust, London, UK
- <sup>m</sup> MRC Clinical Trials Unit, University College London, London, UK
- <sup>n</sup> Portsmouth Hospitals University NHS Trust, Portsmouth, UK
- ° Queen Elizabeth University Hospital, NHS Greater Glasgow & Clyde, Glasgow, UK
- P Wellcome-MRC Institute of Metabolic Science, Department of Clinical Biochemistry, University of Cambridge, Cambridge, UK
- <sup>q</sup> Cancer Research UK Oxford Centre, University of Oxford, Oxford, UK
- NIHR UCLH Clinical Research Facility and NIHR UCLH Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK
- S University Hospitals Sussex NHS Foundation Trust, Brighton, UK
- t Department of Infectious Diseases and Tropical Medicine. London Northwest University Healthcare. London. UK
- <sup>u</sup> lenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK
- The Adam Practice, Poole, UK
- w NIHR Leeds Clinical Research Facility, Leeds Teaching Hospitals Trust and University of Leeds, Leeds, UK
- \* Public Health Wales, Betsi Cadwaladr University Health Board, Bangor University, Bangor, UK
- y University of Liverpool, Liverpool, UK

E-mail address: s.faust@soton.ac.uk (S.N. Faust).

DOI of original article: https://doi.org/10.1016/j.jinf.2022.04.018

<sup>\*</sup> Corresponding author at: NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.

- <sup>2</sup> University Hospitals of Leicester NHS Trust, University of Leicester, Leicester, UK
- <sup>aa</sup> Bradford Institute for Health Research and Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK
- <sup>ab</sup> Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK
- ac MRC University of Glasgow Centre for Virus Research, Glasgow, UK
- <sup>ad</sup> UK Health Security Agency, Porton Down, UK
- ae UK Health Security Agency, Colindale, London, UK
- <sup>af</sup> Division of Epidemiology and Public Health, University of Nottingham School of Medicine, UK

The authors regret that there has been an error published within Fig. 5 of this article. The authors inadvertently pasted the anti-spike plots for the ">70 years" group instead of the pseudo-neutralising antibody plots (pages 808–809) to Fig. 5A and B. These plots replicate the ">70 years" group in Fig. 4A and B on pages 806–807. The authors have confirmed that the error does not affect the

interpretation of the results and the rest of the paper, and the plots for the "<70 years" group in Fig. 5 are correct. The revised Fig. 5 contains the correct plots for pseudo-neutralising antibody data has now been updated in the original publication. The authors would like to apologise for any inconvenience caused.